Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:MAbs
Asıl Yazarlar: Bauer, Joschka, Mathias, Sven, Kube, Sebastian, Otte, Kerstin, Garidel, Patrick, Gamer, Martin, Blech, Michaela, Fischer, Simon, Karow-Zwick, Anne R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2020
Konular:
Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7531517/
https://ncbi.nlm.nih.gov/pubmed/32658605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1787121
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller